In summary, the telmisartan-rosuvastatin treatment combination did not significantly improve insulin resistance, but preserved insulin secretion, improved fasting blood glucose, and reduced the risk of NODM more than the amlodipine-rosuvastatin combination in hypertensive ASCVD patients with IFG. The gene discussed is INS; the disease is Insulin resistance.